Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Shattuck Labs, Inc. (NASDAQ: STTK) announced its participation in two upcoming investor conferences. CEO Taylor Schreiber will speak at the Cowen 41st Annual Health Care Conference on March 2, 2021, and VP Andrew Neill will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune disease treatment, with its lead program SL-172154 currently in a Phase 1 trial. The company also collaborates with Takeda Pharmaceuticals on another candidate, SL-279252.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), announced its participation in Citi's 2021 Virtual Immuno-Oncology Day Conference on February 17-18, 2021. CEO Taylor Schreiber and VP of Finance Andrew Neill will present on the company's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases. Shattuck's lead program, SL-172154, is currently undergoing a Phase 1 trial targeting the CD47 checkpoint, while a second program, SL-279252, is in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, a clinical-stage biotechnology company listed on NASDAQ under the symbol STTK, announced its participation in the H.C. Wainwright BioConnect 2021 Conference, set for January 11-14, 2021. The presentation will be led by Andrew Neill, Vice President of Finance and Corporate Strategy, on January 11 at 6:00 a.m. EST. Attendees can access the session via a dedicated webcast link. Shattuck specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatments.
Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.
Shattuck Labs, a clinical-stage biotechnology firm, announced its inclusion in the Russell 2000® and 3000® Indexes effective December 21, 2020. This milestone is seen as a reflection of investor confidence and is expected to enhance the company's visibility in the investment community, expanding its institutional shareholder base. The Russell indexes, managed by FTSE Russell, are pivotal for asset managers, with about $9 trillion in assets benchmarked against them. Shattuck specializes in bi-functional fusion proteins targeting cancer and autoimmune diseases, including ongoing Phase 1 trials for lead programs.
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.
Shattuck Labs (NASDAQ: STTK) announced the initiation of a Phase 1 clinical trial for its CD47 checkpoint inhibitor, SL-172154, targeting ovarian cancer. The company raised approximately $232.3 million in its October 2020 IPO, extending its cash runway into 2024. Financial results for Q3 2020 show a net loss of $11.8 million, increasing from $7.3 million in Q3 2019. R&D expenses rose to $11.8 million, up from $7.9 million in the same period last year. Shattuck remains focused on advancing its clinical trials and maintaining its pipeline through ongoing funding.
Shattuck Labs, a clinical-stage biotechnology firm (NASDAQ: STTK), announced the presentation of preclinical data from its GADLEN™ platform at the SITC Annual Meeting on November 11, 2020. The research showcases the potential of a butyrophilin heterodimer to activate gamma delta T cells, targeting lymphoma cells with the CD19 antigen. CEO Taylor Schreiber emphasized the promise of enhancing gamma delta T cell effectiveness for treating resistant cancers. This milestone represents significant progress in developing GADLEN compounds for various tumor targets.
Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.
Summary not available.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
